Could a sleep monitor help ALS patients breathe easier?
NCT ID NCT07502677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a wearable device called SleepImage can accurately detect respiratory failure in people with ALS (Lou Gehrig's disease). Researchers will compare the device's readings with standard overnight sleep tests in 15 patients. The goal is to find a simpler way to decide when to start non-invasive ventilation (breathing support), potentially improving quality of life and care timing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SleepImage device (wearable sleep monitor)
- What this could lead to
- If successful, this could provide a simpler, home-based way to detect when ALS patients need breathing support, potentially improving timing of care.
- What could go wrong
- This is a very small early study (15 people) testing a device, not a treatment. The device may not be accurate enough, and results may not apply to all ALS patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Amyotrophic Lateral Sclerosis
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 and over with a Neurologist confirmed diagnosis of ALS Exclusion Criteria: * Patients with known respiratory disease * Unstable cardiac disease, stable hypertension or ischaemic heart disease * Current NIV use * Inability to give consent (expected \~15% due to frontotemporal dementia)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Royal Brompton Hospital
RECRUITINGLondon, sw3 6np, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing device tested to slow lung decline in ALS
- Can hospital codes reliably track home ventilation in ALS?
- Can a synthetic compound be safe enough to test in ALS? early trial asks
- Can a cheap gout drug slow ALS? trial puts colchicine to the test
- Can donor gut bacteria reshape the immune system in ALS?
- Spinal injection drug targets genetic cause of ALS and dementia